Woodmont Investment Counsel LLC Akero Therapeutics, Inc. Transaction History

Woodmont Investment Counsel LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$36.89 - $56.88 $18,445 - $28,440	-500 Reduced 7.02%	6,620 $309,000
Q1 2023 May 09, 2023	SELL	$37.27 - $50.24 $16,771 - $22,608	-450 Reduced 5.94%	7,120 $272,000
Q4 2022 Jan 31, 2023	SELL	$33.44 - $54.8 $68,552 - $112,340	-2,050 Reduced 21.31%	7,570 $414,000
Q3 2022 Nov 08, 2022	SELL	$10.15 - $34.05 $25,375 - $85,125	-2,500 Reduced 20.63%	9,620 $328,000
Q2 2022 Aug 09, 2022	BUY	$8.0 - $15.01 $16,000 - $30,020	2,000 Added 19.76%	12,120 $115,000
Q1 2022 May 12, 2022	BUY	$12.97 - $22.26 $6,485 - $11,130	500 Added 5.2%	10,120 $144,000
Q4 2021 Feb 02, 2022	BUY	$19.87 - $26.24 $191,149 - $252,428	9,620 New	9,620 $203,000

191

74.6M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.62B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Woodmont Investment Counsel LLC, based on Form 13F filings with the SEC.

Stay updated on Woodmont Investment Counsel LLC with notifications on news.